Connor Clark & Lunn Investment Management Ltd. Raises Stock Position in Eli Lilly and Company $LLY

Connor Clark & Lunn Investment Management Ltd. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 23.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,073 shares of the company’s stock after purchasing an additional 8,055 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Eli Lilly and Company were worth $32,797,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter worth $27,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $35,000. TD Capital Management LLC increased its stake in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares in the last quarter. Finally, Iron Horse Wealth Management LLC lifted its position in Eli Lilly and Company by 100.0% during the 1st quarter. Iron Horse Wealth Management LLC now owns 66 shares of the company’s stock valued at $55,000 after acquiring an additional 33 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 4,314 shares of company stock worth $2,766,929 over the last ninety days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $923.35 on Monday. The stock has a market cap of $872.92 billion, a PE ratio of 60.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46. The firm has a fifty day moving average price of $799.97 and a 200-day moving average price of $775.01. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. Finally, Berenberg Bank reissued a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $960.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.